Shorter Radiotherapy Schedule Studied in Women With Endometrial Cancer
Studies a shorter radiation schedule in women with endometrial cancer, tracking side effects over time.
Plain-language title generated from the registry record
Registry title: Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- McGill University Health Centre-Cedars Cancer CentreMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Trial code
- NCT07871838
- Record updated
- 13 October 2026
- Original description
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks.Read full original descriptionShow less
Hypofractionated Endometrial Radiation Outcomes and Safety
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks.
The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is:
How does this particular type of radiotherapy affect the patients in terms of short and long term side effects?
Participants will:
* Visit the clinic for a total of 15 times in 60 months for check ups * Complete a total of 9 questionnaires throughout the 15 visits * Have standard-of-care blood tests and imaging to monitor the cancer response to treatment
Inclusion: Patients 18 years of age or older, ECOG 0-2; Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours; FIGO 2009 stage I-IIIC1 are eligible. 20; Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection); Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion.
Exclusion: Need of a radiotherapy field exceeding the whole pelvis; Para-aortic nodal disease; Non-standard surgery, evidence of residual disease after surgery; Active inflammatory bowel disease; Previous cancer in the last 5 years (except non-melanoma skin cancer); ECOG 3 or higher; Active scleroderma; Patients with contraindication to CT contrast; Inability to achieve dose constraints; Inability to reproduce simulation positioning during treatment.